MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/ccm.0000000000005955

Медицинская библиотека · Critical care medicine · 2023

Sodium Bicarbonate for Metabolic Acidosis in the ICU: Results of a Pilot Randomized Double-Blind Clinical Trial.

Serpa Neto Ary, Fujii Tomoko, McNamara Mairead, Moore James, Young Paul J, Peake Sandra, Bailey Michael, Hodgson Carol, Higgins Alisa M, See Emily J, Secombe Paul, Campbell Lewis, Young Meredith, Maeda Mikihiro, Pilcher David, Nichol Alistair, Deane Adam, Licari Elisa, White Kyle, French Craig, Shehabi Yahya, Cross Anthony, Maiden Matthew, Kadam Umesh, El Khawas Khaled, Cooper Jamie, Bellomo Rinaldo, Udy Andrew

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

To identify the best population, design of the intervention, and to assess between-group biochemical separation, in preparation for a future phase III trial.

DESIGN

Investigator-initiated, parallel-group, pilot randomized double-blind trial.

SETTING

Eight ICUs in Australia, New Zealand, and Japan, with participants recruited from April 2021 to August 2022.

PATIENTS: Thirty patients greater than or equal to 18 years, within 48 hours of admission to the ICU, receiving a vasopressor, and with metabolic acidosis (pH < 7.30, base excess [BE] < -4 mEq/L, and Pa co2 < 45 mm Hg).

INTERVENTIONS: Sodium bicarbonate or placebo (5% dextrose).

MEASUREMENTS AND MAIN RESULT: The primary feasibility aim was to assess eligibility, recruitment rate, protocol compliance, and acid-base group separation. The primary clinical outcome was the number of hours alive and free of vasopressors on day 7. The recruitment rate and the enrollment-to-screening ratio were 1.9 patients per month and 0.13 patients, respectively. Time until BE correction (median difference, -45.86 [95% CI, -63.11 to -28.61] hr; p < 0.001) and pH correction (median difference, -10.69 [95% CI, -19.16 to -2.22] hr; p = 0.020) were shorter in the sodium bicarbonate group, and mean bicarbonate levels in the first 24 hours were higher (median difference, 6.50 [95% CI, 4.18 to 8.82] mmol/L; p < 0.001). Seven days after randomization, patients in the sodium bicarbonate and placebo group had a median of 132.2 (85.6-139.1) and 97.1 (69.3-132.4) hours alive and free of vasopressor, respectively (median difference, 35.07 [95% CI, -9.14 to 79.28]; p = 0.131). Recurrence of metabolic acidosis in the first 7 days of follow-up was lower in the sodium bicarbonate group (3 [20.0%] vs. 15 [100.0%]; p < 0.001). No adverse events were reported.

CONCLUSIONS

The findings confirm the feasibility of a larger phase III sodium bicarbonate trial; eligibility criteria may require modification to facilitate recruitment.

Для цитирования: Serpa Neto Ary, Fujii Tomoko, McNamara Mairead, Moore James, Young Paul J, Peake Sandra, Bailey Michael, Hodgson Carol, Higgins Alisa M, See Emily J, Secombe Paul, Campbell Lewis, Young Meredith, Maeda Mikihiro, Pilcher David, Nichol Alistair, Deane Adam, Licari Elisa, White Kyle, French Craig, Shehabi Yahya, Cross Anthony, Maiden Matthew, Kadam Umesh, El Khawas Khaled, Cooper Jamie, Bellomo Rinaldo, Udy Andrew. Sodium Bicarbonate for Metabolic Acidosis in the ICU: Results of a Pilot Randomized Double-Blind Clinical Trial.. Critical care medicine. 2023. DOI: 10.1097/ccm.0000000000005955.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.